Overview

Explore the impact of the first-line application of Durvalumab combined with Lenvatinib, with or without chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers.

Eligibility

Inclusion Criteria:

• The subjects voluntarily participate in the study and agree to sign the informed consent form, are compliant, and cooperate with follow-up.
• They are over 18 years of age and gender is not restricted when signing the informed consent form.
• They have histologically confirmed unresectable advanced or metastatic biliary tract adenocarcinoma, including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer.
• Patients who are diagnosed with unresectable or metastatic disease and have not received prior treatment are eligible for inclusion.
• Patients who have undergone curative surgery and experienced disease recurrence after more than 6 months; or patients who have completed adjuvant therapy (chemotherapy and/or radiotherapy) and have been disease-free for more than 6 months after completing adjuvant therapy are eligible for inclusion.
• They have at least one measurable lesion (as defined by RECIST 1.1, the measurable lesion is a spiral CT scan long diameter ≥10mm or lymph node short diameter ≥15mm).
• Their ECOG score is 0-1 in the week prior to enrollment.
• Based on the investigator's assessment, their estimated survival time is ≥3 months.
• Patients with active hepatitis B or C require relevant antiviral treatment, with HBV-DNA <2000 IU/ml (<104 copies/ml), and have received at least 14 days of antiviral treatment before participating in the study. HCV RNA-positive patients must follow local standard treatment guidelines for antiviral therapy, and their liver function is within CTCAE Grade 1 elevation.
• Their hematological and organ functions are adequate, based on laboratory test results obtained within 14 days before the start of the study (unless otherwise specified):
• Hematology: (no blood transfusion, no G-CSF, no drug correction within 14 days prior to screening) Hb ≥90 g/L; neutrophil count ≥1.5×109/L; PLT ≥100×109/L.
• Biochemistry: (no albumin transfusion within 14 days) Appropriate liver function: ALT and AST ≤2.5×ULN; for patients with liver metastases, ALT and AST ≤5 × ULN.

        Serum bilirubin ≤2.0×ULN; these conditions do not apply to patients with confirmed
        Gilbert's syndrome. Any clinically significant biliary obstruction should be resolved
        before randomization.
        Appropriate renal function: creatinine ≤1.5×ULN, or creatinine clearance rate (CCr)
        >50mL/min (using the standard Cockcroft-Gault formula):
        Female: CrCl = ((140 - age) x weight (kg) x 0.85) / 72 x serum creatinine (mg/dL) Male:
        CrCl = ((140 - age) x weight (kg) x 1.00) / 72 x serum creatinine (mg/dL)
        ●Women of childbearing potential: agree to abstain from sexual intercourse or use
        contraceptive methods with a failure rate of less than 1% during the treatment period and
        for at least 6 months after the last dose.
        If a female patient has menstruation and has not reached menopause (continuous absence of
        menstruation for ≥12 months without other reasons), and has not undergone sterilization
        surgery (removal of ovaries and/or uterus), she is considered to be of childbearing
        potential.
        Examples of contraceptive methods with a failure rate of less than 1% include bilateral
        tubal ligation, male sterilization, hormone-based contraceptives that inhibit ovulation,
        hormone-releasing intrauterine devices, and copper intrauterine devices.
        The reliability of sexual restraint should be evaluated relative to the duration of the
        clinical trial and the patient's preferred lifestyle and daily routine. Periodic abstinence
        (such as calendar day, ovulation period, symptom temperature, or post-ovulation method) and
        ejaculation outside the vagina are unacceptable contraceptive methods.
        ●Male: agree to abstain from sexual intercourse or use contraceptive measures, agree not to
        donate sperm, as defined below: When the female partner is of childbearing potential, male
        patients must abstain during the treatment period and for 6 months after the last dose, or
        use a condom plus other contraceptive methods to achieve a failure rate of less than 1%.
        Male patients must also agree not to donate sperm during the same period. When the female
        partner is already pregnant, male patients must abstain or use a condom to prevent fetal
        exposure to the study during the treatment period and for 6 months after the last dose.
        The reliability of sexual restraint should be evaluated relative to the duration of the
        clinical trial and the patient's preferred lifestyle and daily routine. Periodic abstinence
        (such as calendar day, ovulation period, symptom temperature, or post-ovulation method) and
        ejaculation outside the vagina are unacceptable contraceptive methods.
        Exclusion Criteria:
          -  Previous systemic treatment received.
          -  ECOG score > 1.
          -  Pancreatic cancer.
          -  Pregnant (positive pregnancy test before medication) or breastfeeding women.
          -  Known allergy or intolerance to recombinant humanized PD-1 monoclonal antibody drugs,
             lenvatinib and its components (or any excipients).
          -  Received local anti-tumor treatment within 4 weeks before the first study drug
             treatment, including but not limited to surgery, radiotherapy, hepatic artery
             embolization, TACE, hepatic artery infusion, radiofrequency ablation, cryoablation, or
             percutaneous ethanol injection (allowing palliative radiotherapy for bone metastases
             at least 2 weeks before study drug treatment).
          -  Previous or existing grade 3 or higher gastrointestinal fistula or
             non-gastrointestinal fistula (such as skin) according to CTCAE 5.0 criteria.
        Multiple factors affecting oral administration of lenvatinib (such as inability to swallow,
        chronic diarrhea and intestinal obstruction, or other conditions that significantly affect
        drug intake and absorption).
          -  Major surgery (except biopsy) has been performed within 4 weeks before the first study
             drug treatment, or the surgical incision has not completely healed; minor surgery
             (such as simple excision, biopsy, etc.) was performed within 7 days before the first
             study intervention.
          -  Significant cardiovascular and cerebrovascular diseases, including but not limited to
             acute myocardial infarction, severe/unstable angina pectoris, cerebrovascular
             accidents or transient ischemic attacks within 6 months before enrollment, congestive
             heart failure (New York Heart Association classification ≥2), arrhythmia requiring
             antiarrhythmic drugs (except beta blockers or digoxin), and repeated electrocardiogram
             showing QTc interval >480 milliseconds (ms).
        Hepatic or renal dysfunction, with manifestations such as jaundice, ascites, and/or
        bilirubin >3×ULN, creatinine ratio >3.5g/24 hours, or renal failure requiring blood or
        peritoneal dialysis, and/or urinary routine showing urine protein ≥++ or confirmed 24-hour
        urine protein quantification >1.0g.
          -  Persistent infection > grade 2 (CTCAE 5.0).
          -  History of thrombotic events (including stroke and/or transient ischemic attacks)
             within the past 6 months.
          -  Poorly controlled hypertension (systolic blood pressure >160mmHg, diastolic blood
             pressure >100mmHg) despite treatment with antihypertensive medications.
        Active autoimmune disease or history of autoimmune disease within the past 2 years;
        participants with active, known, or suspected autoimmune diseases that may affect important
        organ function or require systemic immunosuppressive therapy are excluded, including but
        not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus
        erythematosus, rheumatoid arthritis, antiphospholipid syndrome associated with thrombosis,
        Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis,
        vasculitis, or glomerulonephritis. However, participants with type 1 diabetes,
        hypothyroidism requiring only hormone replacement, skin diseases that do not require
        systemic treatment (such as vitiligo, psoriasis, or alopecia) or participants who will not
        relapse without external triggering factors are allowed. Replacement therapy (such as
        thyroid hormone, insulin, or physiological corticosteroid replacement therapy for adrenal
        or pituitary insufficiency) is not considered a form of systemic treatment.
        ●Known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.
        Participants with previously treated brain metastases may participate as long as they are
        stable (evidence of no progression on imaging at least 4 weeks before the first trial
        treatment and any neurological symptoms have returned to baseline), have no evidence of new
        or enlarging brain metastases, and have not used steroids for at least 7 days before trial
        treatment. This exception does not include carcinomatous meningitis, which is excluded
        regardless of clinical stability. Participants with known or untreated brain metastases or
        epilepsy requiring medication are also excluded.
        Planned or prior organ or allogeneic bone marrow transplantation. Known history of active
        tuberculosis (Mycobacterium tuberculosis). History of gastrointestinal bleeding within the
        past 6 months or clear evidence of gastrointestinal bleeding tendencies, such as bleeding
        esophageal varices, locally active gastrointestinal ulcerative lesions, fecal occult blood
        ≥(++), cannot be included; if fecal occult blood (+), gastroscopy is required; evidence or
        history of bleeding mechanism disorders of grade ≥3 (CTCAE 5.0), or other bleeding
        disorders.
          -  Known human immunodeficiency virus (HIV) infection.
          -  Known active hepatitis B or C infection and not receiving regular treatment.
          -  During the screening period, HBV DNA ≥2000 IU/ml (or ≥104 copies/ml) must be reduced
             to <2000 IU/ml (or <104 copies/ml) with entecavir before enrollment. For eligible
             participants with Anti-HBc (+)/HBsAg (+)/HBV DNA< 2000 IU/ml or Anti-HBc (+)/HBsAg
             (-)/HBV DNA< 2000 IU/ml, antiviral therapy must be administered during the trial
             period using the original medication or entecavir or tenofovir.
          -  Severe non-healing wounds, ulcers, or fractures.
          -  History of substance abuse or any medical, psychological, or social condition that may
             affect the study, patient compliance, or endanger patient safety.
          -  Unresolved toxicity of grade >1 (CTCAE 5.0) caused by any prior treatment/procedure,
             except for hair loss, anemia, and hypothyroidism.
          -  Severe non-healing wounds, ulcers, or fractures.
          -  Objective evidence of severe pulmonary impairment, such as a history of severe
             pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, or
             drug-related pneumonia.
          -  Treatment with a strong CYP3A4 inhibitor (e.g., clarithromycin, indinavir,
             itraconazole, lopinavir, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole,
             etc.) within 7 days before participating in the study, or treatment with a strong
             CYP3A4 inducer (e.g., phenytoin, phenobarbital, primidone, carbamazepine, rifampin,
             rifabutin, rifapentine, or St. John's Wort) within 12 days before participating in the
             study.
          -  Concomitant malignancy, except for previously treated skin basal cell carcinoma,
             squamous cell carcinoma, carcinoma in situ of the breast or cervix, superficial
             bladder cancer that has been treated, and prostate cancer that has been treated with
             surgery and has a normal range of PSA tumor markers, or any other malignancy that has
             not been cured within the past 5 years.
          -  The investigator determines that the participant is unsuitable for the study based on
             overall medical condition.
          -  Concurrent participation in another clinical study.